LON:HEMO

Hemogenyx Pharmaceuticals Final Earnings Results & Report

Hemogenyx Pharmaceuticals logo
GBX 621 -69.50 (-10.07%)
As of 11:58 AM Eastern

Hemogenyx Pharmaceuticals reported Final earnings on April 28, 2025. The company reported EPS of -GBX 181.10.

Earnings Announcement Details

Quarter
Final
Report Date
Time
Before Market Opens

Hemogenyx Pharmaceuticals EPS Results

Actual EPS
-GBX 181.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Hemogenyx Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Hemogenyx Pharmaceuticals Final Earnings FAQ

Hemogenyx Pharmaceuticals (LON:HEMO) reported earnings of -GBX 181.10 per share for Final. The report was announced on Monday, April 28, 2025.

Hemogenyx Pharmaceuticals Earnings Headlines

Hemogenyx Pharmaceuticals PLC - Chairman Receives Prestigious Award
Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
See More Hemogenyx Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hemogenyx Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hemogenyx Pharmaceuticals and other key companies, straight to your email.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals (LON:HEMO), a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.

View Hemogenyx Pharmaceuticals Profile